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InfectionAbstract Current studies continue to show that UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetyl
glucosamine deacetylase (LpxC) inhibitors such as pyridone methylsulfone hydroxymate 1 and 2a
(LpxC-2) downregulate the lethal effects of sepsis initiated by multi-drug resistant Gram-negative
bacteria (MDRGNB) by curtailing lipopolysaccharide (LPS) synthesis in murine models. Sepsis ini-
tiated by MDRGNB is a leading cause of shock and systemic inﬂammatory response syndrome
(SIRS) in intensive care unit (ICU) patients. To date however, the biological effects of LpxC-2
and related molecules in companion and production animals remain largely unexplored in vivo
and are therefore unknown. Such studies would be greatly informative in the expectation of
LpxC-2 progressing to human clinical trials. Mechanistic studies to interrogate this novel antibiotic
candidate in realistic and clinically applicable large animal models of veterinary importance are
sorely lacking. To be relevant, the physiology of the chosen animal models should closely match
that of humans such as ovine or porcine, or even better, non-human primate based studies, as they
are more genetically similar to humans than murine models. If discovered to have subtle or
negligible side effects, LpxC-2 could have a future role in the treatment and management of
MDRGNB-induced infections that lead to sepsis in both animals and humans. More research is
indicated on LpxC-2 use in many veterinary species, as data remains scarce.
ª 2014 Faculty of Veterinary Medicine, Cairo University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Advances in scientiﬁc research have identiﬁed a novel antibiotic
target with the potential to combat multi-drug resistant
Gram-negative bacteria (MDRGNB) infections via enzymaticinhibition of endotoxin biosynthesis [1,2]. The target is
LpxC – a metalloenzyme that catalyses the deacetylation of
UDP-3-O-(R-3-hydroxymyristoyl)-N-acetyl glucosamine, the
ﬁrst committed step in the biosynthesis of lipid A which is an
essential component of the outer membrane of Gram-negative
bacteria [1,3]. Lipid A also protects the bacterium from attack
by many antibiotics and detergents. Due to its ability to block
lipopolysaccharide (LPS) synthesis, pyridone methylsulfone
hydroxymate 1 and 2a (LpxC-2), are members of a class of
antibiotics that do not kill bacteria, but avert their ability
to activate the sepsis cascade by promoting phagocytic
killing [4,5].
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MDRGNB?
Thus far, MDRGNB are the commonest and most important
sepsis-causing pathogens [4]. The selective pressure generated
by antibiotic use has led to the development of antibiotic-
resistant hospital microorganisms that are resistant to com-
monly used antibiotics. This, in some cases has caused hospital
epidemic infections [6]. These organisms have acquired multi-
ple mechanisms of antimicrobial drug resistance. They have
the potential to spread to the community and continue to exert
enormous public health and economic burdens [7,8].
Invasive intensive care procedures, including artiﬁcial
ventilation, transfusion, artiﬁcial organs and long hospital
stays augment the risk of infection with MDRGNB [9]. For
example, MDRGNB-induced sepsis is the most common con-
tributor to the death of patients with ventricular assist devices
[10,11]. Until now, pathogenic MDRGNB have continued to
pose the greatest and most serious health threat of hospital
acquired infections, especially for patients with chronic
indwelling lines or cannulae as they can lead to catheter-related
blood stream infections [8,12]. This cohort of patients includes
those undergoing extra corporeal membranous oxygenation
and blood transfusion [9].
There is need for the development of novel treatment
options to alleviate resistance to antibiotics, for instance those
targeting LPS and fatty acid biosynthesis and shifting from
traditional antibiotic targets [13].
3. Is LpxC-2 the answer to the management of MDRGNB
induced sepsis?
Studies are ongoing on LpxC-2 as a representative of new class
of antibiotics that is reportedly in the ﬁnal stages of testing in
small animals before being trialled clinically [1,3,5]. Inhibition
of LpxC has recently been shown to protect mice from the
lethal effects of sepsis caused by Acinetobacter baumannii, a
MDRGNB, by modulating inﬂammation, enhancing phagocy-
tosis and thereby reducing serum LPS levels [4].
Virulent MDRGNB characteristically shed LPS during
growth, leading to the activation of the sepsis cascade and
culminating in systemic inﬂammatory response syndrome
(SIRS) [4]. Sepsis is an important cause of shock, which affects
millions of people and animals around the world. In people,
for instance, the global incidence of sepsis continues to
escalate. It remains a major cause of death in intensive care
units (ICUs) and the community, and causes a large burden
of disease and has a negative economic impact [14]. An
Australian and New Zealand study calculated the incidence
of severe sepsis in adults treated in ICUs at 0.77 (0.76–0.79)
per 1000 of population [15]. The same study reported that
26.5% of patients with severe sepsis died in the ICU, 32.4%
perished within 28 days of the diagnosis of severe sepsis and
37.5% died in hospital [15].
Irrespective of the species, organ failure is one of the most
severe manifestations of SIRS. Mortality and morbidity are
directly related to the number of failing organs, therefore
preventing the activation of the sepsis cascade is a priority of
LpxC-2 enzymatic activity. The prevention and the treatment
of LPS-initiated sepsis represent the only prospect for
improved survival and quality of life for patients in intensivecare who are at risk of acquiring infections from MDRGNB
[16].
4. Does LpxC-2 have a future use in veterinary medicine
and food animal production?
Resistant strains of bacteria found in animals have mainly
resulted from the use of antimicrobials in veterinary medicine;
and similarly resistant strains of bacteria found in humans are
due the use of antimicrobials in human medicine [17]. The rec-
ognition of companion pet animals as a source of MDRGNB
[18] raises serious concerns due to their close interaction with
humans.
The vast majority of currently used antibiotics were devel-
oped to either inactivate or damage bacteria or both. The
promising aspect of LpxC-2 is that it prevents Gram-negative
bacteria from synthesising LPS, therefore making the bacteria
both unviable and curtailing their production of endotoxin,
allowing the immune system to ﬁght infection more effectively.
This is an attractive attribute of LpxC-2, however, the toxicity
and safety proﬁles, and withdrawal periods in food animals are
still unknown. LpxC-2 could potentially be added to antibiotic
cocktails in bull semen meant for artiﬁcial insemination to
inhibit MDRGNB such as Pseudomonas, Stenotrophomonas
and Sphingomonas spp. that have been identiﬁed as pathogens
affecting animal reproduction [19]. LpxC-2 also has the
potential of being used to mitigate the effects of Salmonella.
Salmonella has been identiﬁed as a major cause of economic
losses in domestic livestock, and is also a serious zoonotic
pathogen worldwide [20]. LpxC-2 could potentially be used
in controlling a wide spectrum of economically important
livestock diseases such as those causing mastitis [21–23],
endometritis, abscesses and general malaise by pathogens such
as Pasteurella multocida [24], and infections caused by several
members of the Enterobacteriaceae family such as Escherichia
coli.
5. What opinions are out there regarding testing LpxC inhibitors
in large animals?
It is true that LpxC inhibitors could be tested in large animals
and their effect in reducing sepsis remains an interesting
possibility that has yet to be demonstrated. However, it should
be realised that LpxC inhibitors are lethal to many Gram-
negative pathogens, including many outlined in this paper.
Acinetobacter is an exception in that certain strains of
Acinetobacter apparently can survive in vitro without lipid A
biosynthesis. However, for the vast majority of Gram-negative
bacteria, this is thought not to be the case, but where is the
evidence? It is known that LpxC inhibitors are not anti-
virulence factors, so antibiotic resistance could rise quickly.
Therefore, the suggestion about using LpxC inhibitors in live-
stock ought to be carefully considered for its potential impact
on humans.
Whilst this is an interesting area for additional research,
LpxC inhibitors have the potential to be very useful in
treatment of infections due to multi-resistant Gram-negative
bacteria. Veterinary or human drug development use of large
animal species in particular is usually called for to validate drug
development. Some authorities however believe that the
emphasis on the use of large animal models, based on
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human perspective is questionable. The relevance of species
used (in the context of human and veterinary drug develop-
ment) should be based on pharmacokinetic, as well as pharma-
codynamic particulars. Further to this, there is no species, not
even humans, that is 100% relevant for humans. From the
pharmacological and mechanistic point of view currently used
standard animal models such as murine models of systemic
and skin and soft tissue infection models have proven useful
in the early phases of the drug development process, prior to
initiation of clinical trials, to establish proof of concept. In sub-
sequent studies where the toxicological proﬁle of the test article
is investigated, two species, one rodent and one non-rodent are
commonly used. The non-rodent species is usually dog and
occasionally monkey, the availability of historical control data
as well as group sizes limit choice of species such as sheep and
bovine in these safety studies. So is there room to explore non-
model species for drug development or this paradigm shift is
contra-indicated?
6. Perspectives
The possibility of investigating the in vivo effects of LpxC-2 in
clinically relevant large animal models needs a serious consid-
eration. Reports on large animal models with the ultimate goal
of characterising the biological effects of LpxC-2 in vivo are
scarce. Well-developed relevant large animal studies such as
those in sheep and swine [25] could provide insights into using
models based on LPS-induced sepsis as a starting point. Estab-
lished large animal studies such as these on LPS could set a
foundation for testing MDRGNB challenge through incre-
mental and validation experiments. Work in this area could
embrace objectives such as the determination of physiological,
haematological, biochemical, immunological, histopatholo-
gical, and inﬂammation effects, and of proteogenomic studies
[26] of LpxC-2 in vivo. The studies should able to determine the
kinetics of LpxC-2 and related molecules in blood, tissues and
urine. Swine may offer many advantages compared to other
experimental large animals for having been extensively studied,
the ease of management and that their physiological attributes
are comparable to those of man [27,28]. Animals such as
baboons offer all the advantages of a large animal and are
comparable with humans in nearly all physiological and immu-
nological aspects [29]. The downside in the use of baboons in
whole animal experiments is that studies that enrol non-human
primates can provoke intense scrutiny from regulatory and
oversight groups [30], potentially making it practically impos-
sible for studies to get initiated.
The use of LPS in initial studies would exclude the effects of
confounders from other live bacterial products that may
independently propagate inﬂammation. It would be interesting
to know if the presence of LpxC-2 has any inﬂuence on
LPS-induced pathology despite the fact that LpxC-2 is
designed to ‘‘merely’’ prevent the synthesis of LPS in live
bacteria. After LPS challenge, further studies could involve
using live pathogenic Gram-negative bacteria. It is also possi-
ble that LpxC-2 may have properties that may inﬂuence
inﬂammation in its own right, rather than through the known
LpxC enzymatic inhibition.
It has so far been documented that LpxC does not share
homology with any known mammalian protein, making it anexcellent target for the design of novel antibiotics [31]. Most
studies however, have largely been in vitro or in mouse models
and so studies involving large animals should be conducted in
anticipation of the advancement of LpxC inhibitors into
human clinical trials [1,3,5]. While there is dissenting debate
that animal-based research has been unable to predict human
response to drugs because animals and humans have different
evolutionary trajectories, the alternative view is that animal
models should be genetically closer to that of humans to be rel-
evant [32]. Observations from small animal models may not be
relevant in humans, for instance, current evidence points out
that mouse models are remote from human conditions
[32,33]. The body size similarities, repeated sampling and the
opportunity for continuous invasive monitoring are some of
the major beneﬁts of large animal experimental models [34].
Moreover, the translational beneﬁt of animal studies has been
shown to help to identify and minimise the chances of iatro-
genic harm during critical care situations. This underscores
the need to design experiments to understand the pharmacoki-
netic, pharmacological and side effects of LpxC-2 in the pres-
ence of simulated infection, which are currently unknown in
large animals in vivo.
The beneﬁt of trialling LpxC in relevant large animal
models might help in understanding the ﬁght against sepsis
in man. The community beneﬁts could include optimum health
outcomes because of decreased morbidity and mortality, all of
which translate to improved economic productivity. Similar
beneﬁts are expected in animal patients as well. For now, more
data is needed regarding the effects of LpxC-2 use in well-
designed large animal studies. In summary, very little is known
about the effects of LpxC-2 in large animals and any new
information would make a useful contribution to science and
medicine.
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